Literature DB >> 19909896

The newer fluoroquinolones.

Maureen K Bolon1.   

Abstract

Clinicians have enthusiastically used fluoroquinolones owing to their good safety profile and wide range of indications. This article reviews fluoroquinolone pharmacology, pharmacodynamic principles, and fluoroquinolone resistance mechanisms, highlighting recent trends in the epidemiology of fluoroquinolone resistance among gram-negative organisms and Streptococcus pneumonia. Important fluoroquinolone safety concerns are discussed, along with indications for the most commonly used fluoroquinolones-ciprofloxacin, levofloxacin, and moxifloxacin.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19909896     DOI： 10.1016/j.idc.2009.06.003

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  20 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Piperonal ciprofloxacin hydrazone induces growth arrest and apoptosis of human hepatocarcinoma SMMC-7721 cells.

Authors:  Zhen-yu Shi; Yong-qiang Li; Yu-hua Kang; Guo-qiang Hu; Chao-shen Huang-fu; Jin-Bo Deng; Bin Liu
Journal:  Acta Pharmacol Sin       Date:  2012-02       Impact factor: 6.150

3.  Biophysical Studies of Bacterial Topoisomerases Substantiate Their Binding Modes to an Inhibitor.

Authors:  CongBao Kang; Yan Li; Joseph Cherian; Boping Liu; Hui Qi Ng; Michelle Yueqi Lee; Nur Huda Binte Ahmad; Zhi Ying Poh; Yun Xuan Wong; Qiwei Huang; Ying Lei Wong; Alvin W Hung; Jeffrey Hill; Thomas H Keller
Journal:  Biophys J       Date:  2015-11-03       Impact factor: 4.033

4.  JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains.

Authors:  David J Farrell; Lisa C Liverman; Douglas J Biedenbach; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

Review 5.  The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens.

Authors:  Y-H Chen; W-C Ko; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-04       Impact factor: 3.267

6.  Determination of disk diffusion and MIC quality control guidelines for JNJ-Q2, a novel quinolone.

Authors:  James E Ross; Lisa C Liverman; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

7.  [Antimicrobial and clinical efficacy of nitrofurantoin in the treatment of acute lower urinary tract infections in adults].

Authors:  Arturo Mendoza-Valdes; Alejandra Rosete; Esteban Rios Bueno; Adrian Frentzel; Sonja Trapp; Wilhelm Kirch; Edgar A Mueller
Journal:  Med Klin (Munich)       Date:  2010-10

8.  Severity of infection following the introduction of new infection control measures for medical abortion.

Authors:  Mary Fjerstad; James Trussell; E Steve Lichtenberg; Irving Sivin; Vanessa Cullins
Journal:  Contraception       Date:  2010-10-08       Impact factor: 3.375

9.  Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa: The Importance of the CLSI Breakpoints Revision.

Authors:  Ying Wang; Xinping Zhang; Xuemei Wang; Xiaoquan Lai
Journal:  Infect Drug Resist       Date:  2021-08-31       Impact factor: 4.003

Review 10.  Bullied no more: when and how DNA shoves proteins around.

Authors:  Jonathan M Fogg; Graham L Randall; B Montgomery Pettitt; De Witt L Sumners; Sarah A Harris; Lynn Zechiedrich
Journal:  Q Rev Biophys       Date:  2012-07-31       Impact factor: 5.318
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.